How Phil. was paid
$1.4M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Other | Total |
|---|---|---|---|---|---|---|
| Iain Dukes, D. Phil.Chief Executive Officer | $539,000 | $237,375 | $86,077 | $539,472 | — | $1,401,924 |
| Werner Cautreels, Ph.D.Former Chief Executive Officer | $166,577 | — | $11,356 | $118,801 | $57,163 | $353,897 |
| Charles PauzaChief Science Officer | $500,000 | $180,000 | $43,037 | $269,696 | $21,307 | $1,014,040 |
| Nikolay Savchuk, Ph.D.Chief Operating Officer | $350,000 | $126,000 | $38,256 | $220,554 | — | $734,810 |
What changed and why
- $1.4M$1,401,924 was CEO Iain Dukes’ total compensation in 2025.
- $539K$539,472 in option awards comprised the largest component of Dukes’ 2025 compensation.
- 50%50% was the target annual bonus for Dukes under his employment agreement.
- $354K$353,897 was Werner Cautreels’ total compensation after retiring as CEO effective March 31, 2025.
- $45,000$45,000 of Cautreels’ 2025 all-other compensation was for board service.
- $1M$1,014,040 was Chief Science Officer Charles Pauza’s total compensation in 2025.
Other Traws Pharma proxy statements
- 2025 proxy statement
Werner Cautreels, Ph.D. paid $647,582.
Filed Oct 08, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.